Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIC-IC: Nirmatrelvir/Ritonavir in Immunocompromised COVID-19 Patients
NCT05438602Phase 2Completed
- Sponsor
- Pfizer
- Start
- Aug 2022
- Primary completion
- Jul 2023
- Modality
- Orthosteric Ligands
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Pfizer. Primary endpoint: Percentage of Participants With Sustained Nasopharyngeal SARS-CoV-2 RNA < LLOQ. Started Aug 2022; status: completed.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05438602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05438602.